Abstract
The variability of tumour responses to chemotherapeutic agents is a topic of major interest in current oncology research. Advances in the knowledge of molecular pathology of cancer make available strategies by which tumour cells can be profiled for their genetic background in order to select anticancer agents that might selectively kill cells in a molecular context that matches the mechanism of action of drugs. The next generation of anticancer treatments might thus be tailored on the basis of the numerous molecular alterations identified in tumour cells of a particular patient. However, to exploit these alterations, it is necessary to understand how they influence the cellular pathways that control the sensitivity or, conversely, resistance to chemotherapeutic agents. The aim of this article is to outline major genetic abnormalities in non-Hodgkin lymphomas that can be used to streamline anticancer drug selection and to underscore the major role of pharmacogenetics, which studies the interactions between genetic background and drug activity, to the prediction of likelihood of response and identification of potential new targets for pharmacological intervention. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B and Mohammad RM (1998) Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4: 1305–1314
Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E and Gil J (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94: 2836–2843
Byrd JC, Grever MR, Waselenko JK, Willis CR, Park K, Goodrich A, Lucas MA, Shinn C and Flinn IW (2000) Theophylline, Pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. Semin Oncol 2, (Suppl 5):37–40
Cinatl J Jr, Kotchetkov R, Groschel B, Cinatl J, Driever PH, Kabickova H, Kornhuber B, Schwabe D and Doerr HW (1998) Azidothymidine resistance of H9 human T-cell lymphoma cells is associated with decreased sensitivity to antitumor agents and inhibition of apoptosis. Int J Mol Med 2: 685–691
Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W and Lichter P (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580–1589
Dolan ME, McRae BL, Ferries-Rowe E, Belanich M, van Seventer GA, Guitart J, Pezen D, Kuzel TM and Yarosh DB (1999) O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res 5: 2059–2064
Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A and Mackey J (1999) Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 106: 78–85
Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW and O’Connor PM (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824–5830
Fan S, Cherney B, Reinhold W, Rucker K and O’Connor PM (1998) Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4: 1047–1054
Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W and Huang P (2000) Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med 5: 597–604
Fisher RI (2000) Current therapeutic paradigm for the treatment of non-Hodgkin’s lymphoma. Semin Oncol 27, (Suppl 12):2–8
Frank DA (1999) STAT signaling in the pathogenesis and treatment of cancer. Mol Med 5: 432–456
Fujimori A, Harker WG, Kohlhagen G, Hoki Y and Pommier Y (1995) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to campothecin. Cancer Res 55: 1339–1346
Gottardi D, De Leo AM, Alfarano A, Stacchini A, Circosta P, Gregoretti MG, Bergui L, Aragno M and Caligaris-Cappio F (1997) Fludarabine ability to down-regulate Bcl-2 gene product in CD5+leukaemic B cells: in vitro/in vivo correlations. Br J Haematol 99: 147–157
Groves FD, Linet MS, Travis LB and Devesa SS (2000) Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92: 1240–1251
Haldar S, Basu A and Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229–233
Han SS, Chung ST, Robertson DA, Ranjan D and Bondada S (1999) Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, Bcl-xl, NF-kappa B, and p53. Clin Immunol 93: 152–161
Harvey S, Decker R, Dai Y, Schaefer G, Tang L, Kramer L, Dent P and Grant S (2001) Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin Cancer Res 7: 320–330
Hirose M and Kuroda Y (1998) p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines. Cancer Lett 129: 165–171
Johnston JB, Daeninck P, Verburg L, Lee K, Williams G, Israels LG, Mowat MRA and Begleiter A (1997) P53, MDM-2, BAX, and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 26: 435–449
Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J and Reed JC (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91: 3379–3389
Kitada S, Zapata JM, Andreeff M and Reed JC (2000) Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapopotosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393–397
Kobzdej M, Matuszyk J, Ziolo E and Strzadala L (2000) Changes in glucocorticoid-induced apoptosis and in expression of Bcl-2 protein during long-term culture of thymic lymphoma. Arch Immunol Ther Exp 48: 43–46
Lum BL, Kaubisch S, Fisher GA, Brown BW and Sikic BI (2000) Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother Pharmacol 45: 305–311
Ma Z, Cools J, Marynen P, Cui X, Siebert R, Gesk S, Schlegelberger B, Peeters B, De Wolf-Peeters C, Wlodarska I and Morris SW (2000) Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 95: 2144–2149
Meguerian-Bedoyan Z, Lamant L, Hopfner C, Pulford K, Chittal S and Delsol G (1997) Anaplastic large cell lymphoma of maternal origin involving the placenta: case report and literature survey. Am J Surg Pathol 21: 1236–1241
Michelutti A, Michieli M, Damiani D, Melli C, Ermacora A, Grimaz S, Candoni A, Russo D, Fanin R and Baccarani M (1997) Effect of fludarabine and arabinosylcytosine on multidrug resistant cells. Haematologica 82: 143–147
Minn AJ, Rudin CM, Boise LH and Thompson CB (1995) Expression of Bcl-xl can confer a multidrug resistance phenotype. Blood 86: 1903–1910
Muller C, Christodoulopoulos G, Salles B and Panasci L (1998) DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 92: 2213–2219
Muthukkumar S, Ramesh TM and Bondada S (1995) Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 60: 264–270
Navaratnam S, Williams GJ, Rubinger M, Pettigrew NM, Mowat MR, Begleiter A and Johnston JB (1998) Expression of p53 predicts treatment failure in aggressive non-Hodgkin’s lymphomas. Leuk Lymphoma 29: 139–144
O’Connor PM, Wassermann K, Saragan M, Magrath I, Bohr VA and Kohn KW (1991) Relationship between DNA cross-links, cell cycle and apoptosis in Burkitt’s lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res 51: 6550–6557
Pepper C, Thomas A, Hidalgo De Quintana J, Davies S, Hoy T and Bentley P (1999) Pleiotropic drug resistance in B-cell chronic lymphocytic leukemia-the role of Bcl-2 family dysregulation. Leuk Res 23: 1007–1014
Reed JC, Kitada S, Takayama S and Miyashita T (1994) Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin’s lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5: 61–65
Ribrag V, Massade L, Faussat AM, Dreytus F, Bayle C, Gouyette A and Marie JP (1996) Drug resistance mechanisms in chronic lymphocytic leukemia. Leukemia 10: 1944–1949
Rowley M, Liu P and Van Ness B (2000) Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood 96: 3175–3180
Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR and Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670–2677
Schmitt E, Steyaert A, Cimoli G and Bertrand R (1998) Bax-alpha promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells. Cell Death Differ 5: 506–516
Schröder JK, Kirch C, Flasshove M, Kalweit H, Seidelmann M, Hilger R, Seeber S and Schütte J (1996) Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside. in vitro. Leukemia 10: 1919–1924
Silber R, Degar B, Costin D, Newcomb EW, Mani M, Rosenberg CR, Morse L, Drygas JC, Canellakis ZN and Potmesil M (1994) Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 84: 3440–3446
Simonian PL, Grillot DA and Nunez G (1997) Bcl-2 and Bcl-xl can differentially block chemotherapy-induced cell death. Blood 90: 1208–1216
Sundaresan A, Claypool K, Mehta K, Lopez-Berestein G, Cabanillas F and Ford RJ Jr (1997) Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ 8: 1071–1082
Taylor ST, Hickman JA and Dive C (2000) Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst 92: 18–23
Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C and Lichtenstein A (1996) Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 88: 1805–1812
Valkov NI and Sullivan DM (1997) Drug resistance to DNA topoisomerase I and II inhibitors in human leukaemia, lymphoma, and multiple myeloma. Semin Hematol 34: 48–62
Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA and Fisher RI (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 19: 389–397
Walton MI, Whysong D, O’Connor PM, Hockenbery D, Korsmeyer SJ and Kohn KW (1993) Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53: 1853–1861
Webb M, Brun M, McNiven M, Le Couteur D and Craft P (1998) MDR1 and MPR expression in chronic B-cell lymphoproliferative disorders. Br J Haematol 102: 710–717
Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM and Monks A (2000) Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. Clin Cancer Res 6: 415–421
Wong SJ, Myette MS, Wereley JP and Chitambar CR (1999) Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clinical Cancer Research 5: 439–443
Zaja F, Di Loreto C, Amoroso V, Salmaso F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L, Mariuzzi L, Beltrami CA and Baccarani M (1998) BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. Leuk Lymphoma 28: 567–572
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Loni, L., Del Tacca, M. & Danesi, R. Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas. Br J Cancer 85, 1425–1431 (2001). https://doi.org/10.1054/bjoc.2001.2130
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2130